News and Events

News

All categories

Earnings

Press Release

All years

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Announces Full Year 2018 Financial Results Conference Call on March 27, 2019

March 20, 2019

Affimed Announces Milestone Payment from Genentech and ROCK^® Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity

March 19, 2019

Affimed to Present Data on AFM13 and AFM24 at AACR Annual Meeting 2019

February 27, 2019

Affimed to Present at Upcoming Investor Conferences

February 21, 2019

Affimed to Present at the 37th Annual J.P. Morgan Healthcare Conference

January 4, 2019

Affimed Announces U.S. Registrational Pathway and Updated Clinical Development Plan for AFM13 at R&D Day

December 7, 2018

Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors

December 3, 2018

Affimed to Host Research & Development Day on Friday, December 7, 2018 in New York City

November 28, 2018

Affimed to Present at the Jefferies 2018 London Healthcare Conference

November 8, 2018

Affimed Reports Financial Results for Third Quarter 2018 and Operational Progress

November 7, 2018

Events

All

Scientific

Investors

28Mar

Innate Killer Summit

March 28 - 30, 2023 (San Diego, USA)

14Apr

AACR Annual Meeting 2023

April 14 - 19, 2023 (Orlando, Florida)

23Apr

EBMT 49th Annual Meeting

April 23 - 26, 2023 (Paris, France)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Announces Full Year 2018 Financial Results Conference Call on March 27, 2019

Affimed Announces Milestone Payment from Genentech and ROCK^® Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity

Affimed to Present Data on AFM13 and AFM24 at AACR Annual Meeting 2019

Affimed to Present at Upcoming Investor Conferences

Affimed to Present at the 37th Annual J.P. Morgan Healthcare Conference

Affimed Announces U.S. Registrational Pathway and Updated Clinical Development Plan for AFM13 at R&D Day

Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors

Affimed to Host Research & Development Day on Friday, December 7, 2018 in New York City

Affimed to Present at the Jefferies 2018 London Healthcare Conference

Affimed Reports Financial Results for Third Quarter 2018 and Operational Progress

Events

Innate Killer Summit

AACR Annual Meeting 2023

EBMT 49th Annual Meeting